[go: up one dir, main page]

PE20201448A1 - Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos - Google Patents

Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos

Info

Publication number
PE20201448A1
PE20201448A1 PE2020001613A PE2020001613A PE20201448A1 PE 20201448 A1 PE20201448 A1 PE 20201448A1 PE 2020001613 A PE2020001613 A PE 2020001613A PE 2020001613 A PE2020001613 A PE 2020001613A PE 20201448 A1 PE20201448 A1 PE 20201448A1
Authority
PE
Peru
Prior art keywords
methyl
haloalkyl
halo
alkyl
chloro
Prior art date
Application number
PE2020001613A
Other languages
English (en)
Inventor
Alexandre Côte
Victor S Gehling
Avinash Khanna
Ludivine Moine
Jacob I Stuckey
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of PE20201448A1 publication Critical patent/PE20201448A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS BICICLICOS DE FORMULA (I) DONDE R1 ES HALO, -S-ALQUILO(C1-C4), -S-CICLOALQUILO(C3-C7) O -S-HALOALQUILO(C1-C4); X ES CH O N; R2 ES H, HALO, ALQUILO(C1-C4) O HALOALQUILO(C1-C4); R3 ES HALO, ALQUILO(C1-C4) O HALOALQUILO(C1-C4); R4 ES CICLOALQUILO(C3-C7) O HETEROCICLILO DE 4-7 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON 1 A 3 GRUPOS SELECCIONADOS DE HALO, ALQUILO(C1-C4), HALOALQUILO(C1-C4), ENTRE OTROS; R5 ES HALO, ALQUILO(C1-C4) O HALOALQUILO(C1-C4). SON COMPUESTOS PREFERIDOS: 7-CLORO-2-(4-(3-(DIFLUOROMETOXI)AZETIDIN-1-IL)CICLOHEXIL)-2,4-DIMETIL-N-((6-METIL-4-(METILTIO)-2-OXO-1,2-DIHIDROPIRIDIN-3-IL)METIL)BENZO[D][1,3]DIOXOL-5-CARBOXAMIDA; 7-CLORO-N-((4-CLORO-6-METIL-2-OXO-1,2-DIHIDROPIRIDIN-3-IL)METIL)-2-(4-(3-METOXIAZETIDIN-1-IL)CICLOHEXIL)-2,4-DIMETILBENZO[D][1,3]DIOXOL-5-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE ENZIMAS MODIFICADORAS DE METILO SIENDO UTILES PARA EL TRATAMIENTO DE CANCER DE PROSTATA, CANCER DE MAMA, CANCER DE COLON.
PE2020001613A 2018-04-18 2019-04-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos PE20201448A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659408P 2018-04-18 2018-04-18
PCT/US2019/027932 WO2019204490A1 (en) 2018-04-18 2019-04-17 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
PE20201448A1 true PE20201448A1 (es) 2020-12-10

Family

ID=66429588

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001613A PE20201448A1 (es) 2018-04-18 2019-04-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos

Country Status (34)

Country Link
US (3) US10689371B2 (es)
EP (2) EP4421072A1 (es)
JP (2) JP7256823B2 (es)
KR (2) KR102798145B1 (es)
CN (2) CN119954787A (es)
AR (1) AR114793A1 (es)
AU (1) AU2019255310B2 (es)
BR (1) BR112020021194A2 (es)
CL (1) CL2020002698A1 (es)
CO (1) CO2020014217A2 (es)
CR (1) CR20200553A (es)
DK (1) DK3781561T3 (es)
EA (1) EA202092490A1 (es)
ES (1) ES2983344T3 (es)
FI (1) FI3781561T3 (es)
HR (1) HRP20240793T1 (es)
HU (1) HUE066783T2 (es)
IL (1) IL278013B2 (es)
LT (1) LT3781561T (es)
MA (1) MA52288B1 (es)
MD (1) MD3781561T2 (es)
MX (1) MX2020010999A (es)
MY (1) MY208662A (es)
PE (1) PE20201448A1 (es)
PH (1) PH12020551578A1 (es)
PL (1) PL3781561T3 (es)
PT (1) PT3781561T (es)
RS (1) RS65621B1 (es)
SG (1) SG11202009438UA (es)
SI (1) SI3781561T1 (es)
SM (1) SMT202400233T1 (es)
TW (1) TWI828677B (es)
UA (1) UA127357C2 (es)
WO (1) WO2019204490A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3781561T (lt) 2018-04-18 2024-07-10 Constellation Pharmaceuticals, Inc. Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
BR112022001154A2 (pt) * 2019-07-24 2022-06-07 Constellation Pharmaceuticals Inc Terapias de inibição de ezh2 para o tratamento de cânceres
PE20220562A1 (es) * 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
WO2021180235A1 (zh) * 2020-03-13 2021-09-16 四川海思科制药有限公司 Zeste增强子同源物2抑制剂及其用途
CN113666920B (zh) * 2020-04-14 2025-10-03 浙江华海药业股份有限公司 苯并恶唑类化合物制备方法及其在医药领域的应用
JP7720846B2 (ja) * 2020-07-08 2025-08-08 第一三共株式会社 １，３－ベンゾジオキソール誘導体の製造方法
DK4247371T3 (da) * 2020-11-18 2025-03-31 Constellation Pharmaceuticals Inc Ezh2-hæmningsterapier til behandling af androgenreceptor-muterede prostatacancere
KR102872076B1 (ko) 2021-01-11 2025-10-15 주식회사 엘지에너지솔루션 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법
JP7799847B6 (ja) * 2022-01-14 2026-02-10 トンファ ファーム カンパニー リミテッド １，３－ベンゾジオキソール誘導体化合物およびそれを含む薬剤学的組成物
CN116496263A (zh) * 2022-01-27 2023-07-28 江苏天士力帝益药业有限公司 Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
EP4536649A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
EP4536658A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
JP2025528837A (ja) 2022-08-17 2025-09-02 インサイト・コーポレイション 抗ｃｄ１９抗体及びｅｚｈ２モジュレーターを含む治療
WO2025008783A1 (ko) * 2023-07-06 2025-01-09 동화약품주식회사 1,3-벤조다이옥솔 유도체 화합물을 포함하는 약학적 조성물
TW202542136A (zh) * 2023-12-15 2025-11-01 大陸商格物生物技術（江蘇）有限公司 １，３－苯并二氧雜環戊烯衍生物以及其用途

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
CA2004670A1 (en) 1988-12-08 1990-06-08 Jan Hartog Anxiolytically active piperazine derivatives
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
EP0883403B1 (en) 1996-01-29 2010-08-25 The Regents of The University of California Method for treating sexual dysfunctions
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
PT1026950E (pt) 1997-10-27 2006-06-30 Cortex Pharma Inc Tratamento da esquizofrenia com ampaquinas e neurolepticos
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
EP1384713B1 (en) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-amino-azepan-3-one derivatives as protease inhibitors
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US7115615B2 (en) 2000-08-21 2006-10-03 Astrazeneca Quinazoline derivatives
AU2001281246A1 (en) 2000-08-23 2002-03-04 The Procter And Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
DK2264018T3 (en) 2000-08-24 2015-05-11 Univ Pittsburgh Thioflavin derivatives for use in diagnosis of Alzheimer's disease
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
MXPA04009896A (es) 2002-04-09 2005-06-17 Novogen Res Pty Ltd Metodos terapeuticos y composiciones que implican estructuras de tipo isoflav-3-eno e isoflavano.
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
ES2301833T3 (es) 2002-07-29 2008-07-01 Hoffmann La Roche Derivados de benzodioxol.
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
EP1542654A4 (en) 2002-09-23 2008-12-17 Novogen Res Pty Ltd TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN
EP1648452B1 (en) 2003-07-28 2009-07-22 Merck Serono SA 2-imino-4-(thio)oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1685140A4 (en) 2003-11-18 2009-02-25 Novogen Res Pty Ltd PRODRUGS BASED ON ISOFLAVONOIDS, COMPOSITIONS THEREOF AND THERAPEUTIC PROCESSES INVOLVING THEM
US20060167037A1 (en) 2003-11-19 2006-07-27 Kelly Graham E Combinational radiotherapy and chemotherapy compositions and methods
EP1711467A2 (en) 2004-01-16 2006-10-18 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
RU2006138603A (ru) 2004-04-07 2008-05-20 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
EP1751124A4 (en) 2004-05-07 2010-04-14 Exelixis Inc RAF MODULATORS AND METHODS OF USE
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
EP1807075A2 (en) 2004-10-12 2007-07-18 Applied Research Systems ARS Holding N.V. Pi3 kinase gamma inhibitors for the treatment of anaemia
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
WO2006090930A1 (ja) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の新規併用
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20080194552A1 (en) 2005-03-31 2008-08-14 Astrazeneca Ab Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
CA2604836A1 (en) 2005-04-08 2006-10-19 Bayer Pharmaceuticals Corporation Pyrimidine derivatives and their use in the treatment of cancer
PL1881823T3 (pl) 2005-05-17 2015-05-29 Sarcode Bioscience Inc Kompozycje i sposoby leczenia chorób oczu
MX2007014773A (es) 2005-05-25 2008-02-20 Wyeth Corp Metodo para preparar 3-ciano-quinolinas e intermedios hechos de esta forma.
WO2006129609A1 (ja) 2005-05-30 2006-12-07 Shionogi & Co., Ltd. ２－ナフチルイミノ－５，５－ジ置換－１，３－チアジン誘導体
JP2008545744A (ja) 2005-06-02 2008-12-18 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト フェニルアルキル置換ヘテロアリール誘導体
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007014154A2 (en) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
JP5066088B2 (ja) 2005-08-04 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ セロトニン受容体モジュレーターとしてのピリミジン化合物
EP1932837A4 (en) 2005-08-17 2011-05-25 Daiichi Sankyo Co Ltd HETEROCYCLIC BICYCLOUS BINDING WITH ANTIPILY EFFECT
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
CA2648785A1 (en) 2006-03-23 2007-09-27 Prolysis Ltd. Antibacterial agents
CA2653769A1 (en) 2006-05-30 2007-12-06 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
US20100035877A1 (en) 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
AU2007314141A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
EA017249B8 (ru) 2007-05-10 2013-01-30 Олбани Молекьюлар Рисерч, Инк. Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
CA2958665C (en) 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
KR101773313B1 (ko) 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
CN102131777B (zh) 2008-06-23 2014-03-19 詹森药业有限公司 Ccr2的哌啶基丙烯酰胺拮抗剂
WO2010019772A2 (en) 2008-08-14 2010-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxides as antischistosomal agents
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
US9206173B2 (en) 2009-05-28 2015-12-08 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of stress-related conditions
AU2010270153A1 (en) 2009-07-10 2012-02-02 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis C NS5B polymerase, the pharmaceutical composition thereof and their therapeutic use
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
EP2513268B1 (en) 2009-12-17 2019-02-20 The Lubrizol Corporation Use of an aromatic compound as antiwear agent in lubricants
EP2528922B1 (en) 2010-01-27 2017-08-02 AB Pharma Ltd Polyheterocyclic compounds as hcv inhibitors
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
US20130338153A1 (en) 2010-06-10 2013-12-19 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
WO2012013725A1 (en) 2010-07-28 2012-02-02 Medizinische Universität Wien Vinylogous chalcone derivatives and their medical use
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
TW201225957A (en) 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
WO2012045196A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Phosphoglycerate kinase inhibitors
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JPWO2013065835A1 (ja) 2011-11-04 2015-04-02 味の素株式会社 糖尿病治療用医薬組成物
AU2013216721B2 (en) 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
RU2015111206A (ru) 2012-08-30 2016-10-20 Ниппон Синяку Ко., Лтд. Пиридиновое производное и лекарственное средство
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
SG10201806965XA (en) 2013-03-13 2018-09-27 Boston Biomedical Inc 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
WO2014177464A2 (en) 2013-04-30 2014-11-06 Heinrich-Heine-Universität Düsseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
JP6353054B2 (ja) 2013-09-09 2018-07-04 ヤンジェン セラピューティクス カンパニー リミテッド Ｃ−アリールグルコシド誘導体、その製造方法およびその医薬適用
WO2015069110A1 (en) 2013-11-07 2015-05-14 Aapa B.V. Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
KR102302830B1 (ko) * 2014-03-17 2021-09-15 다이이찌 산쿄 가부시키가이샤 1,3-벤조디옥솔 유도체
DK3157915T3 (en) 2014-06-17 2019-04-23 Pfizer Substituted dihydroisoquinolinone compounds
AU2015313829B2 (en) 2014-09-11 2020-07-23 Piramal Enterprises Limited Fused heterocyclic compounds as GPR120 agonists
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2993605C (en) 2015-07-30 2020-01-07 Daiichi Sankyo Company, Limited 1,3-benzodioxole derivatives for the treatment or prevention of adult t cell leukemia/lymphoma
KR20180098369A (ko) 2016-01-13 2018-09-03 그뤼넨탈 게엠베하 3-((헤테로-)아릴)-알킬-8-아미노-2-옥소-1,3-디아자-스피로-[4.5]-데칸 유도체
RU2018128334A (ru) 2016-02-09 2020-03-10 Инвентисбио Инк. Ингибиторы индоламин-2,3-диоксигеназы (ido)
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
TW201831181A (zh) 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
US11466020B2 (en) 2017-03-17 2022-10-11 Cornell University Compounds and compositions for inhibition and elimination of Zika infection and uses for same
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
WO2019084271A1 (en) 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
JP2021510733A (ja) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
US20210093591A1 (en) 2018-03-30 2021-04-01 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Methods for mitigating and preventing proteostasis-based injuries
LT3781561T (lt) 2018-04-18 2024-07-10 Constellation Pharmaceuticals, Inc. Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas

Also Published As

Publication number Publication date
IL278013A (en) 2020-11-30
SG11202009438UA (en) 2020-11-27
CL2020002698A1 (es) 2021-01-15
HUE066783T2 (hu) 2024-09-28
WO2019204490A1 (en) 2019-10-24
US11274095B2 (en) 2022-03-15
US20190322651A1 (en) 2019-10-24
EP3781561A1 (en) 2021-02-24
US20240116905A1 (en) 2024-04-11
CR20200553A (es) 2021-04-08
SI3781561T1 (sl) 2024-08-30
JP2023082132A (ja) 2023-06-13
EP3781561B1 (en) 2024-03-13
ES2983344T3 (es) 2024-10-22
EA202092490A1 (ru) 2020-12-23
CA3098428A1 (en) 2019-10-24
EP4421072A1 (en) 2024-08-28
CN111989325B (zh) 2025-02-25
MD3781561T2 (ro) 2025-02-28
AU2019255310A1 (en) 2020-10-15
RS65621B1 (sr) 2024-07-31
UA127357C2 (uk) 2023-07-26
FI3781561T3 (fi) 2024-06-13
JP7256823B2 (ja) 2023-04-12
SMT202400233T1 (it) 2024-07-09
PL3781561T3 (pl) 2024-07-22
LT3781561T (lt) 2024-07-10
KR20250073166A (ko) 2025-05-27
HRP20240793T1 (hr) 2024-09-13
MY208662A (en) 2025-05-22
TW202003505A (zh) 2020-01-16
KR20210003160A (ko) 2021-01-11
MA52288A (fr) 2021-04-07
US20200317651A1 (en) 2020-10-08
MA52288B1 (fr) 2024-07-31
PH12020551578A1 (en) 2021-09-13
BR112020021194A2 (pt) 2021-03-23
CO2020014217A2 (es) 2021-03-08
MX2020010999A (es) 2021-01-20
US10689371B2 (en) 2020-06-23
DK3781561T3 (da) 2024-06-17
KR102798145B1 (ko) 2025-04-22
CN119954787A (zh) 2025-05-09
JP2021522166A (ja) 2021-08-30
AR114793A1 (es) 2020-10-14
IL278013B1 (en) 2023-09-01
TWI828677B (zh) 2024-01-11
PT3781561T (pt) 2024-06-18
CN111989325A (zh) 2020-11-24
IL278013B2 (en) 2024-01-01
AU2019255310B2 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20211911A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20211698A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20181198A1 (es) Derivados de heterociclos biciclicos condensados como agentes de control de plagas
PE20191020A1 (es) Compuestos quimicos
PE20171329A1 (es) Agentes inmunorreguladores
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20090730A1 (es) Derivados de piridina como moduladores de los canales de sodio
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20171514A1 (es) Heterociclos biciclicos como inhibidores de fgfr
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20150352A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
PE20020470A1 (es) Derivados de pirazol como inhibidores de las enzimas proteina quinasas
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
PE20070854A1 (es) Compuestos heterociclos como agonistas del receptor de acido nicotinico